Evaluation of Injectable PRF With Vitamin D As an Adjunct to Non-Surgical Therapy in the Treatment of Stage III Periodontitis. A Randomized Controlled Clinical Trial

a clinical trial will be made to investigate the effect of locally applied injectable prf (iPRF) plus vitamin D on the periodontal pockets in stage III periodontitis patients

Start Date01 Oct 2024

Sponsor / Collaborator

Cairo University

CTRI/2024/08/072307 / Not yet recruitingNot ApplicableIIT

Effect of Oral Vitamin D Supplementation on Post Orthodontic Relapse in Vitamin D Insufficient Individuals - A Quasi Experimental Study - NIL

Start Date02 Sep 2024

Sponsor / Collaborator-

IRCT20240702062312N1 / RecruitingPhase 3IIT

The effects of two training program and vitamin D supplementation on lipid profile, leptin and body composition in obese adolescents with vitamin D deficiency

Start Date20 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Vitamin D

100 Translational Medicine associated with Vitamin D

100 Patents (Medical) associated with Vitamin D

71,987

Literatures (Medical) associated with Vitamin D

31 Dec 2024·Annals of Medicine

Relationship between remnant cholesterol and risk of kidney stones in U.S. Adults: a 2007–2016 NHANES analysis

Article

Author: Yang, Peigang ; Yao, Lei

PURPOSERemnant cholesterol (RC) is the cholesterol content of triglyceride-rich lipoproteins. This study aimed to investigate the association between RC levels and kidney stones in U.S. adults.METHODSData were obtained from the 2007 to 2016 National Health and Nutrition Examination Survey (NHANES). A total of 10,551 participants with complete data were included and analyzed in this study. Univariate and multivariate logistic regression analysis, restricted cubic spline function, subgroup analysis and mediation analysis were preformed to estimate the independent relationship between RC levels and kidney stones.RESULTSParticipants with stone formation had higher levels of RC than those with without stone formation (25.78 ± 13.83 vs 23.27 ± 13.04, p< 0.001). The results of logistic regression analysis and dose-response risk curves revealed a positive nonlinear association between RC levels and risk of kidney stones [univariate: adjusted odds ratio (aOR) =2.388, 95% CI: 1.797-3.173, p< 0.001; multivariate: aOR = 1.424, 95% CI: 1.050-1.929, p = 0.023]. Compared with the discordantly low RC group, the discordantly high RC group was associated with increased risk of kidney stones (aOR = 1.185, 95% CI: 1.013-1.386, p= 0.034). Similar results were demonstrated according to the discordance of different clinical cut points. And metabolic syndrome parameters and vitamin D levels parallelly mediated the association between RC and kidney stone risk.CONCLUSIONSHigher RC levels were independently associated with an increased risk of kidney stone incidence.

31 Dec 2024·Renal Failure

Risk factors and clinical prediction models for osteoporosis in pre-dialysis chronic kidney disease patients

Article

Author: Kuang, Chaoying ; Guan, Baozhang ; Zhong, Yuzhen ; Chen, Liangmei ; Yan, Bing ; Shang, Jingjie ; Ma, Mingming ; Liu, Fanna ; Gong, Jian ; Huang, Shengling

BACKGROUNDOsteoporosis in pre-dialysis chronic kidney disease (CKD) patients has been overlooked, and the risk factors of osteoporosis in these patients have not been adequately studied.OBJECTIVETo identify risk factors for osteoporosis in pre-dialysis CKD patients and develop predictive models to estimate the likelihood of osteoporosis.METHODSDual-energy X-ray absorptiometry was used to measure bone mineral density, and clinical examination results were collected from 326 pre-dialysis CKD patients. Binary logistic regression was employed to explore the risk factors associated with osteoporosis and develop predictive models.RESULTSIn this cohort, 53.4% (n = 174) were male, 46.6% (n = 152) were female, and 21.8% (n = 71) were diagnosed with osteoporosis. Among those diagnosed with osteoporosis, 67.6% (n = 48) were female and 32.4% (n = 23) were male. Older age and low 25-(OH)-Vitamin D levels were identified as risk factors for osteoporosis in males. For females, older age, being underweight, higher bone alkaline phosphatase (NBAP), and advanced CKD (G5) were significant risk factors, while higher iPTH was protective. Older age, being underweight, and higher NBAP were risk factors for osteoporosis in the G1-4 subgroup. In the G5 subgroup, older age and higher NBAP increased the risk, while high 25-(OH)-Vitamin D or iPTH had protective effects. Nomogram models were developed to assess osteoporosis risk in pre-dialysis patients based on gender and renal function stage.CONCLUSIONRisk factors for osteoporosis vary by gender and renal function stages. The nomogram clinical prediction models we constructed may aid in the rapid screening of patients at high risk of osteoporosis.

31 Dec 2024·Gynecological Endocrinology

Postmenopausal women with higher TSH values within the normal range present improved handgrip strength: a pilot study

Article

Author: Kaparos, George ; Vlachos, Nikolaos ; Armeni, Eleni ; Lambrinoudaki, Irene ; Chedraui, Peter ; Panoulis, Konstantinos ; Augoulea, Areti ; Kontou, Loraina ; Palaiologou, Anastasia ; Chatzivasileiou, Panagiota ; Alexandrou, Andreas

OBJECTIVETo evaluate the possible association between thyroid function within the euthyroid range and musculoskeletal parameters as well as body composition in a sample of postmenopausal women.METHODSThis cross-sectional study included 96 postmenopausal women with serum thyroid-stimulating hormone (TSH) within the normal laboratory reference range. Fasting venous blood samples were obtained for biochemical/hormonal assessment. Bone status and body composition were measured using Dual Energy X-ray absorptiometry (DXA). Physical activity was quantified using the International Physical Activity Questionnaire (IPAQ) index.RESULTSSerum TSH correlated with handgrip strength (HGS, r-coefficient = 0.233, p = .025), and total body bone mineral density (BMD) T-score values (r-coefficient = 0.321, p = .003). HGS measures were associated with BMD (r-coefficient = 0.415, p < .001), with bone mineral content (BMC, r-coefficient = 0.427, p < .001), and lean mass (r-coefficient = 0.326, p = .003). Women with low muscle strength, defined as HGS < 16 kg, had lower TSH levels than women with normal muscle strength (low vs. normal muscle strength, ANCOVA 1.13 ± 0.49 mU/L vs. 1.60 ± 0.83 mU/L, p = 0.024) independently of age, BMD, percentage of body fat or absolute lean mass. Multivariable linear regression analysis showed that HGS values were associated with TSH measurements (β-coefficient = 0.246, p = .014) and BMD T-score values (β-coefficient = 0.306, p = .002). All models were adjusted for age, body mass index (BMI), vitamin D, low-density lipoprotein cholesterol, current smoking, physical activity, and homeostasis model assessment of insulin resistance.CONCLUSIONSIn this sample of postmenopausal women, lower serum TSH values, within normal range, were associated with lower muscle strength compared to higher normal TSH values. Further research is needed to elucidate the significance of our preliminary findings.

News (Medical) associated with Vitamin D

04 Jul 2024

·www.biospace.com

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

MONTREAL, July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed. TransConTM PTH is a parathyroid hormone (PTH) replacement therapy designed to treat chronic hypoparathyroidism, a rare condition caused by absent or insufficient levels of PTH. It is approved under the brand name YORVIPATH® in the European Union, European Economic Area, and Great Britain as a PTH replacement therapy for the treatment of adults with chronic hypoparathyroidism1. TransConTM PTH is also in development for the treatment of adults with chronic hypoparathyroidism in the United States, Japan, and other countries. A leading Canadian Parathyroidologist Dr Aliya Khan noted that TransConTM PTH will be the first approved treatment option available to Canadian patients living with chronic hypoparathyroidism. "Hypoparathyroidism can seriously impact quality of life and has potentially life-threatening consequences," Dr Khan said. "To have an option that is able to treat the underlying cause of the disease, moving beyond standard oral calcium and active vitamin D, is a great step forward." "This partnership represents Pendopharm's commitment to bringing innovative medicines that address unmet medical needs to Canadian patients," said Jad Isber, VP and GM of Pendopharm. "We look forward to working with Canadian endocrinologists to make TransConTM PTH available to all patients who may benefit from it." Ascendis Pharma Executive Vice President and Chief Commercial Officer Camilla Harder Hartvig said "We are delighted to partner with Pendopharm to bring TransConTM PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism." This new partnership aligns with Pharmascience's ambition to establish itself as a leading organization in the life sciences ecosystem. "We are excited by the addition of TransConTM PTH to our portfolio and the life-changing impact it will have on patients. Our wide range of generic and specialty products demonstrates Pharmascience's continued commitment to improve access to medicines and bring new innovation for patients in Canada and globally" stated Martin Arès, Chief Executive Officer of Pharmascience. © 2024 Pendopharm, division of Pharmascience Inc. All rights reserved. About Pendopharm Pendopharm, a division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine and orthopedics, neurology and cardiology. Pendopharm has extensive experience and knowledge to successfully manage its growing product portfolio. Additional information: About Pharmascience Inc. Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience's global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients' needs. About Ascendis Pharma Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of Patients, Science and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. About TransConTM PTH (palopegteriparatide) TransConTM PTH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24-hour dosing period. YORVIPATH was granted marketing authorization by the European Commission (EC) and European Economic Area (EEA) in November 2023 and by the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) in April 2024 as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In the United States, the U.S. Food & Drug Administration (FDA) has set a PDUFA date of August 14, 2024 to complete their review of Ascendis Pharma's New Drug Application for TransCon PTH for adults with chronic hypoparathyroidism. TransCon PTH is also in development in Japan through Teijin Ltd. and in China through VISEN Pharmaceuticals. About Hypoparathyroidism Hypoparathyroidism is an endocrine disease caused by insufficient levels of PTH, the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestine. Hypoparathyroidism is considered chronic if it persists >12 months following surgery per the 2022 Guidelines from the Second International Workshop.2 Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune, genetic, and idiopathic causes. References YORVIPATH (palopegteriparatide) EU Summary of Product Characteristics. Khan AA, Rubin MR, Schwarz P, et al. J Bone Miner Res. 2023;38(1):14–25. SOURCE Pendopharm Company Codes: NASDAQ-NMS:ASND

Drug ApprovalLicense out/in

28 Jun 2024

·www.sciencedaily.com

New model could help provide expectant mothers a clearer path to safe fish consumption

Research creates a framework to better balance the nutritional benefit of fish consumption with the risk of mercury exposure to the developing brain. Fish consumption during pregnancy is a complex scientific topic. On one hand, fish are rich in nutrients essential to brain development, including polyunsaturated fatty acids, selenium, iodine, and vitamin D. On the other, fish contain methyl mercury, a known neurotoxicant. This has led the US Food and Drug Administration to recommend that expectant mothers limit consumption, which inadvertently causes many women to forgo fish consumption during pregnancy altogether. Fish consumption is an important route of methyl mercury exposure, however, efforts to understand the health risk posed by mercury are further complicated by the fact that the nutritional benefits from fish may modify or reduce the toxicity posed by mercury. A new study appearing in the American Journal of Epidemiology based on data from a cohort of residents of a coastal community in Massachusetts creates a new framework that could untangle these questions, reduce confusion, and produce clearer guidance on fish consumption for pregnant mothers. "We propose an alternative modelling approach to address limitations of previous models and to contribute thereby to improved evidence-based advice on the risks and benefits of fish consumption," said the authors, who include Sally Thurston, PhD, with the University of Rochester Medical Center, Susan Korrick, MD, MPH, with Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital, and David Ruppert, PhD, with Cornell University. "In fish-eating populations, this can be addressed by separating mercury exposure into fish intake and average mercury content of the consumed fish." The new research comes from an analysis of data from the New Bedford Cohort, which was created to assess the health of children born to mothers residing near the New Bedford Harbor Superfund site in Massachusetts. The current study included 361 children from the cohort who were born between 1993 and 1998 and underwent neurodevelopment assessments, including tests for IQ, language, memory, and attention, at age eight years. The researchers were able to measure mercury exposure during the third trimester of pregnancy through hair sample collected from the mothers after birth. While hair samples have been the traditional method to study maternal mercury exposure, this approach alone cannot distinguish between mothers who frequently consumed low-mercury fish compared to those who consumed a smaller quantity of high-mercury fish. To overcome this limitation, the researchers instead created a model that includes estimates of mercury exposure per serving of fish. This was possible because mothers in the cohort also completed a food questionnaire and reported the type and frequency of fish and shellfish consumed during pregnancy. The authors estimated the average mercury levels by type of fish, and when combined with the information about the mother's diet, they were able to create a more precise and detailed method to estimate the joint associations of pregnancy fish intake and fish mercury levels on neurodevelopment. Using this model, the researchers found that the relation between pregnancy fish consumption and subsequent neurodevelopment varied depending on the estimated average mercury levels in the fish. Specifically, consuming low mercury-containing fish was beneficial, while consuming fish with higher levels of mercury was detrimental. "Given methodologic limitations to previous analyses, future work expanding our alternative modelling approach to account for both the average mercury and nutritional content of fish could facilitate better estimation of the risk-benefit tradeoffs of fish consumption, a key component of many healthy diets," said the authors. The authors are in the process of applying this model to other large studies of maternal fish consumption, including the Seychelles Child Development Study, which Thurston serves on as an investigator. The American Journal of Epidemiology study was supported with funding from the National Institute of Environmental Health Sciences.

Clinical Result

10 Jun 2024

·www.drugs.com

MONDAY, June 10, 2024 -- Empiric vitamin D supplementation is suggested for those aged 1 to 18 years, those older than 75 years, those who are pregnant, and those with high-risk prediabetes, according to an Endocrine Society clinical practice guideline published online June 3 in the Journal of Clinical Endocrinology & Metabolism . Marie B. Demay, M.D., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues developed clinical guidelines for use of vitamin D to lower the risk for disease among individuals without indications for vitamin D treatment. The researchers suggest empiric vitamin D supplementation for children aged 1 to 18 years to prevent nutritional rickets and for the potential to reduce the risk for respiratory tract infections; for adults aged 75 years and older due to the potential for reducing mortality risk; for pregnant women due to the potential for reducing the risk for preeclampsia, intrauterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes due to the potential reduction in the risk for progression to diabetes. The optimal doses for empiric vitamin D supplementation remain unclear. The panel suggests supplementation via daily administration of vitamin D for nonpregnant people older than 50 years for whom vitamin D is indicated, and suggests against empiric vitamin D supplementation above the current dietary reference intake to reduce risk among healthy adults younger than 75 years. There was no evidence found to support routine 25-hydroxyvitamin D screening in the general population. "Healthy populations who may benefit from higher dose vitamin D supplements are those 75 and older, pregnant people, adults with prediabetes, and children and adolescents 18 and younger, but we do not recommend routine testing for vitamin D levels in any of these groups," Demay said in a statement. Authors disclosed ties to Amgen and Dexcom. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Vitamin D

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01126671 (CTgov)	Not Applicable	Vitamin D Deficiency	56	Supplemental Vitamin D (Low Dose Vitamin D)	immzmmzvex(jsvvhzoujh) = rropywsvzb hooghtezyf (addhbboxwz, rqhldqfrls - rmjtyqtkom) View more	-	19 Apr 2013
				Supplemental Vitamin D (High Dose Vitamin D)	immzmmzvex(jsvvhzoujh) = ysxxtxxpqf hooghtezyf (addhbboxwz, kwdvqsclvl - qfkcuzitfy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vitamin D

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation